Sarepta therapeutics announces positive functional results from srp-9003 (myo-101) gene therapy trial to treat limb-girdle muscular dystrophy type 2e, or beta-sarcoglycanopathy

Sarepta therapeutics announces positive functional results from the srp-9003 (myo-101) gene therapy trial to treat limb-girdle muscular dystrophy type 2e, or beta-sarcoglycanopathy.sarepta therapeutics inc - significant reduction in creatine kinase maintained over nine months.sarepta therapeutics inc - improvements on functional measures seen in all three participants.sarepta therapeutics - no new safety signals were observed and safety profile seen to date supports ability to dose escalate in next cohort of study.
SRPT Ratings Summary
SRPT Quant Ranking